Watch our Latest Webinar: "Unlocking the Glycoproteome: Utilizing a Robust AI/ML Based Platform for Biomarker Discovery"

Be part of the breakthrough

At InterVenn Biosciences, we’ve developed a platform to unlock the glycoproteome, thereby enabling novel insights into disease biology. With access to this hidden layer of biology, we have the opportunity to uncover novel solutions to previously unsolvable problems, leading to breakthrough discoveries in precision medicine.

GET BEHIND THE SHIFT FROM DISEASE MANAGEMENT TO PREVENTIVE CARE

Interested in joining our mission as an investor?

Help advance precision medicine by joining our mission as an investor

Current Investors

Latest News & Perspectives

InterVenn Biosciences Announces the Publication of Early Detection of Advanced Adenoma and Colorectal Cancer in Gastroenterology, the Flagship Journal of the American Gastroenterological Association

Business Wire | October 13, 2023

Read More

InterVenn Biosciences Welcomes Accomplished Diagnostics Executive Joshua Stahl as CEO

Business Wire | September 27, 2023

Read More

InterVenn Biosciences to Present Clinical Data on Circulating Serum Glycoproteins for Unprecedented Pre-Cancer Detection as “Poster of Distinction” at Digestive Disease Week 2023

Business Wire | April 19, 2023

Read More

Get in touch